HYHao Yao

Hao Yao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hao Yao has a total of 127 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CAR T-cell vs bispecific antibodies in relapsed/refractory mantle cell lymphoma: a systematic review and meta-analysis

    by Meng-Jiao Li, Ling Qiu, Dan Chen, Cai-Yang Li, Ying He, Yan-Ling Li, Ya-Li Cen, Shi-Hui Ren, Hao Yao, Fang-Yi Fan

    Background: Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma with limited treatment options for relapsed/refractory (R/R) cases. CAR T-cell therapy and CD20×CD3 bispecific antibodies are promising immunotherapies, but no study has systematically compared their efficacy and safety in R/R MCL. Methods: This systematic review and meta-analysis was conducted in accordance with the PRISMA 2020 guidelines and registered in PROSPERO (CRD42024622564). A comprehensive search of PubMed, Embase, and the Cochrane Library (from inception to October 27, 2024) was performed to identify studies evaluating CAR T-cell therapy and bispecific antibodies in R/R MCL (third-line or later). Random-effects and fixed-effects models were used to calculate pooled complete response (CR) rates, overall response (OR) rates, and Grade ≥3 adverse events. Sensitivity analyses were conducted to assess the robustness of the results. Results: Five studies (237 patients) were included. Pooled CR rates were 0.63(95% CI, 0.51-0.74)for bispecific antibodies and 0.70(95%CI, 0.63-0.77) for CAR T-cell therapy (P <0.05). OR rates were similar (0.75 vs. 0.88). Grade ≥3 cytokine release syndrome rates were comparable (0.06 vs. 0.06), but neurotoxicity cannot be compared. Conclusion: CAR T-cell therapy demonstrated higher CR rates versus bispecific antibodies, supporting their role as effective third-line treatments for R/R MCL. Randomized trials are needed to confirm these findings. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/ , identifier CRD42024622564.

  • Open Access

    Age-related differences in clinical characteristics and survival in lung cancer

    by Huan-Yu Wang, Ting-Ting Chen, Yu-Jie Zhong, Wei Zhao, Hao Yao, Li-Jie Ma

    Background: Lung cancer predominantly affects older adults; however, an increasing number of cases are diagnosed in younger patients. Age-related differences in baseline characteristics, survival outcomes, and prognostic factors remain incompletely understood. This study aimed to compare clinical features, laboratory profiles, and survival outcomes between young and elderly patients with lung cancer and to identify prognostic factors associated with overall survival (OS) and progression-free survival (PFS). Methods: This retrospective cohort study screened patients with pathologically confirmed primary lung cancer diagnosed in 2022. Patients aged ≤45 years were classified as the young group, and those aged ≥75 years as the elderly group. Baseline demographic characteristics, laboratory parameters, and nutritional–inflammatory indices were compared between groups. Survival outcomes were evaluated using Kaplan–Meier analyses and compared with the log-rank test. Univariate and multivariate Cox proportional-hazards regression analyses were performed to identify prognostic factors for OS and PFS. Results: A total of 44 patients were included (21 young, 23 elderly). Elderly patients had higher smoking exposure and worse nutritional and inflammatory profiles, including lower albumin and prognostic nutritional index values. Younger patients showed significantly longer OS, while PFS was numerically longer but not statistically significant despite a tendency toward more advanced disease. In univariate analyses, histology type, gene mutation status, and treatment modality were associated with survival outcomes. In the simplified multivariable Cox models, immunotherapy was independently associated with improved OS, and targeted therapy, surgery, and immunotherapy were associated with better PFS. Conclusions: Young and elderly patients with lung cancer exhibit distinct clinical, laboratory, and survival profiles. Younger patients demonstrated more favorable genomic profiles and survival outcomes. These findings highlight the importance of age-specific evaluation and suggest that treatment-related and host-related factors should be considered in prognostic assessment.

  • Open Access

    Self-disgust and its associated factors among patients with malignant lymphoma: a latent profile analysis

    by Fang Liao, Ya-Ling Chen, Shan-Shan Zhang, Yu-Hang Song, Zhi-Ling Chen, Hao Yao, Hai Yi, Dan Chen

    To evaluate the severity and independent predictors of self-disgust in patients with malignant lymphoma, and to develop and internally validate a clinical

  • Organoids in biliary tract cancers: Advances in modeling strategies and translational applications

    by Xiao-Hu Yang, Dong-Yang Liu, Wei Zhao, Cheng-Wei Yang, Jun-Xia Wang, Hao Yao

  • Open Access

    Mesenchymal stem cells in intrahepatic and extrahepatic biliary diseases: mechanisms and therapeutic applications

    by Meng-Jiao Li, Wei Zhao, Cai-Yang Li, Yan-Ling Li, Shi-Hui Ren, Jia-Jia Li, Ling Qiu, Cheng-Wei Yang, Fang-Yi Fan, Hao Yao

    Mesenchymal stem cells (MSCs) have emerged as promising therapeutic candidates for a wide range of intrahepatic and extrahepatic biliary diseases. However, their clinical application remains limited by an incomplete understanding of underlying mechanisms and heterogeneous therapeutic outcomes. This review provides a comprehensive overview of recent advances in MSC-based therapies for biliary system diseases, including primary biliary cholangitis, intrahepatic biliary fibrosis and cirrhosis, biliary atresia, primary sclerosing cholangitis, and cholangiocarcinoma. We summarize both preclinical and clinical evidence and focus on key therapeutic mechanisms, including immunomodulation, antifibrotic activity, regulation of bile acid metabolism, and protection of biliary epithelial cells.

  • Open Access

    Efficacy and safety of BCMA-directed CAR T-cell therapy in extramedullary relapsed or refractory multiple myeloma: a meta-analysis

    by Yan-Ling Li, Meng-Jiao Li, Jia-Jia Li, Dan Chen, Cai-Yang Li, Ling Qiu, Ying He, Jian-Chun Fan, Shi-Hui Ren, Hao Yao, et al.

    Background: This meta-analysis systematically evaluated the efficacy and safety of B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory multiple myeloma (RRMM) with extramedullary disease (EMD). Methods: PubMed, Embase, Web of Science, and the Cochrane Library were searched for studies published up to December 2024 reporting CAR T-cell therapy in RRMM patients with EMD. Studies were screened according to predefined inclusion and exclusion criteria. Data were extracted and the methodological quality was assessed using the Newcastle–Ottawa Scale (NOS) and the MINORS tool; one low-quality study was excluded. A total of 42 studies were included, comprising 242 RRMM patients with EMD and 1,485 without EMD. Fixed- or random-effects models were applied to pool effect sizes. Primary outcomes included objective response rate (ORR), complete response (CR), progression-free survival (PFS), and overall survival (OS). Secondary outcomes included cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). Results: The pooled ORR and CR rates were 79% (95%CI: 71%–86%) and 42% (95%CI: 32%–51%) in the EMD group, and 90% (95%CI: 86%–93%) and 49% (95%CI: 40%–58%) in the non-EMD group, respectively. Reported median PFS ranged from 3 to 18.8 months in the EMD grouPand from 1 to 38 months in the non-EMD group, while median OS ranged from 6 to 13.9 months and from 12.2 to 38 months, respectively. The pooled incidences of grade ≥3 CRS and ICANS were 18% (95%CI: 8%–27%) and 5% (95%CI: 3%–7%) in the EMD group, compared with 13% (95%CI: 7%–19%) and 6% (95%CI: 2%–9%) in the non-EMD group; none of the differences were statistically significant (P> 0.05). Due to inconsistent reporting and lack of individual patient-level data, hazard ratios and pooled time-to-event analyses were not feasible. Conclusion: Although RRMM patients with EMD exhibited lower ORR and CR rates than those without EMD, BCMA-directed CAR T therapy demonstrated notable clinical activity with a manageable safety profile. However, no direct comparisons with conventional therapies were performed in this analysis. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42025613422 , identifier CRD42025613422.


  • Open Access

    Zanubrutinib enhances CD19 CAR T killing of B-cell lymphoma by inhibiting BTK phosphorylation, regulating PI3K/AKT/mTOR pathway, and promoting autophagy

    by Hao Yao, Ling Qiu, Shi-Hui Ren, Dan Chen, Meng-Jiao Li, Bai-Tao Dou, Nan Zhang, Xiao Wang, Yi Su, Alex H. Chang, et al.

    Anti-CD19 chimeric antigen receptor T cells (CAR T) still have many limitations, including insufficient clinical efficacy. Zanubrutinib is a second-generation Bruton tyrosine kinase (BTK) inhibitor with higher drug potency, and it is not clear whether it has an enhanced killing effect of CD19 CAR T on B-cell lymphoma. Therefore, this study will investigate the role and mechanism of zanubrutinib in CD19 CAR T therapy against B-cell lymphoma. B-cell lymphoma cells Daudi were proportionally co-cultured with CD19 CAR T and intervened using different concentrations of zanubrutinib, and the changes of cell viability, apoptosis, autophagy, and phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) pathway-related factors were assessed using the Cell Counting Kit-8 (CCK-8) assay, flow cytometry, Western blotting, transmission electron microscopy, and immunofluorescence staining. Also, the effect of zanubrutinib on the sensitivity of B-cell lymphoma mice to CAR T-cell therapy was observed. The results showed that zanubrutinib increased the sensitivity of B-cell lymphoma to CD19 CAR T-cells, promoted apoptosis and autophagy, and inhibited BTK phosphorylation and the PI3K/AKT/mTOR signaling pathway. Zanubrutinib can promote the killing of B-cell lymphoma by CD19 CAR T. Collectively, zanubrutinib enhances CD19 CAR T killing of B-cell lymphoma by inhibiting BTK phosphorylation, regulating PI3K/AKT/mTOR pathway, and promoting autophagy.

  • SETD2 inhibited T-cell acute lymphocytic leukemia invasion and infiltration by inhibiting the JAK/STAT pathway

    by Ling Qiu, Shihui Ren, Mengjiao Li, Baitao Dou, Dan Chen, Nan Zhang, Jiao Cai, Hao Yao, Fangyi Fan

    T-cell acute lymphocytic leukemia (T-ALL) is a malignant transformation of immature precursor T-cells that is highly aggressive. The disruption of SETD2 is thought to be a unique epigenetic mechanism for leukemia. This study aimed to investigate the role and possible mechanism of SETD2 in T-ALL. The expression of SETD2 in T-ALL tissues and cells was detected by RT-PCR, and siRNA (si-NC/si-SETD2) and overexpressed plasmids (ov-NC/ov-SETD2) were used to transfected T-ALL cell lines JURKAT and MOLT-4, and cell proliferation, migration/invasion and cell cycle were detected by CCK8, Transwell, flow cytometry, respectively. WB was used to detect the changes in the JAK/STAT pathway. The JAK/STAT inhibitor AG490 was further used to demonstrate the role of JAK/STAT in SETD2 regulation of T-ALL. Then, the effects of SETD2 on T-ALL tissue infiltration were verified in vivo. Results showed that SETD2 was significantly lowly expressed in T-ALL, and si-SETD2 promoted the proliferation, migration, invasion, cell cycle, and activation of the JAK/STAT pathway of T-ALL cells, while overexpression of SETD2 showed the opposite inhibitory effect. The use of AG490 inhibited the promoting effect of si-SETD2 on T-ALL, suggesting that JAK/STAT was involved in the regulation of SETD2 on T-ALL. In vivo experiments further confirmed that silencing SETD2 decreased the body weight of mice and increased the infiltration of JURKAT cells in the liver, kidney, spleen, lung, and brain, while overexpression of SETD2 showed inhibitory effects. In conclusion, SETD2 played an important role in T-ALL by inhibiting the JAK/STAT pathway to inhibit T-ALL proliferation, invasion, and transfection.

  • Open Access

    The NREP-GPX4 Axis Regulates Epithelial-Mesenchymal Transition and Enhances EGFR-TKI Resistance in Lung Adenocarcinoma Cells

    by Wen-Xiang Wei, Qiu-Li Li, Wei Yang, Ming-Jing Cai, Wen-Jing Dai, Huan-Yu Wang, Yu-Jie Zhong, Tao Zhang, Hao Yao, Li-Jie Ma

    Background: Lung adenocarcinoma (LUAD) is a leading cause of cancer-related deaths worldwide. Despite the advent of targeted therapies, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), the development of resistance remains a significant challenge. Neuronal Regeneration-Related Protein (NREP) has been implicated in promoting drug resistance in various cancers, but its role in EGFR-TKI resistance in LUAD remains underexplored. Additionally, glutathione peroxidase 4 (GPX4), a key regulator of oxidative stress, may interact with NREP to influence drug resistance mechanisms. This study investigates the role of NREP and GPX4 in regulating EGFR-TKI resistance in LUAD cells. Methods: In this study, we used gefitinib-sensitive (PC9) and gefitinib-resistant (PC9/GR) LUAD cell lines to explore the combined effects of NREP and GPX4. Overexpression and knockdown of NREP and GPX4 were achieved using plasmid transfection and siRNA, respectively. Cell viability was assessed using CCK-8 assays. Apoptosis was analyzed by flow cytometry, and invasion was evaluated through Transwell assays. The expression of EMT markers (CD133, α-SMA) and GPX4 was determined by Western blotting and immunofluorescence. The effects of NREP and GPX4 on cell migration and EMT induction were assessed under gefitinib treatment conditions. Results: Overexpression of NREP and GPX4 in PC9 cells enhanced resistance to gefitinib, promoted EMT, and increased invasion, whereas knockdown of NREP and GPX4 in PC9/GR cells sensitized them to gefitinib and reduced invasion. Western blot and immunofluorescence analysis showed upregulation of EMT markers (CD133, α-SMA) and GPX4 in NREP overexpressing cells, while knockdown of NREP and GPX4 led to decreased expression of these markers. Additionally, NREP and GPX4 synergistically activated EMT and invasion in drug-resistant cells. Conclusions: The NREP-GPX4 axis plays a pivotal role in mediating EMT and promoting EGFR-TKI resistance in LUAD. Targeting this axis may offer a novel therapeutic strategy to overcome resistance to EGFR inhibitors and improve treatment outcomes in LUAD patients.

  • Open Access

    CAR T-cells vs. bispecific antibodies as third- or later-line treatment for relapsed/refractory follicular lymphoma: a literature review and meta-analysis

    by Ying He, Ling Qiu, Dan Chen, Shi-Hui Ren, Ya-Xin Xiong, Meng-Jiao Li, Bai-Tao Dou, Yan-Ling Li, Ya-Li Cen, Yun-Ming Li, et al.

    Background: Relapsed/refractory follicular lymphoma (R/R FL) remains a significant challenge in oncology, particularly for patients who have exhausted standard treatment options. Both chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies(BsAb) have emerged as promising therapeutic modalities in this setting, offering novel mechanisms of action and the potential for improved outcomes. However, comparative data on the efficacy and safety of these treatments remain limited. This study aims to evaluate the clinical outcomes and safety profiles of CAR T-cell therapy versus BsAb as third- or later-line treatments for R/R FL.Methods: A systematic review and meta-analysis were conducted to compare the efficacy and safety of CAR T-cell therapy and BsAb in patients with R/R FL. Studies were selected based on predefined inclusion criteria, and relevant data were extracted to assess overall response rates (ORR), complete remission (CR) rates, progression-free survival (PFS), and the incidence of adverse events, including cytokine release syndrome (CRS) and neurotoxicity. Statistical analyses were performed using random-effects models to account for variability across studies.Results: The analysis included 12 studies, with a total of 1,200 patients. CAR T-cell therapy demonstrated superior efficacy compared to BsAb, with a higher ORR (92% vs. 77%)[95% confidence interval (CI) 0.77-0.90] (p= 0.01)and CR rate (82% vs. 65%) [95% CI 0.65-0.80] (p< 0.001). The median PFS was significantly longer for CAR T-cell therapy (15 months) compared to BsAb (9 months). Adverse events were more common in the CAR T-cell group, particularly neurotoxicity (7%[95% CI 0.02-0.13]). However, the overall safety profile was manageable, with most adverse events being grade 1–2 in severity. BsAb were associated with a lower incidence of severe adverse events but showed less favorable efficacy outcomes.Conclusions: Our meta-analysis suggests that CAR T-cell therapy demonstrates a trend toward improved efficacy outcomes compared to bispecific antibodies (BsAb) in R/R FL, with higher response rates and longer PFS. However, this observed advantage must be interpreted cautiously due to potential confounders, including imbalances in baseline tumor burden, prior treatment lines, refractoriness to prior therapy, and variations in bridging therapy protocols across studies. Notably, CAR T-cell therapy was associated with a higher incidence of severe adverse events, particularly neurotoxicity. These findings indicate that while CAR T-cell therapy represents a promising therapeutic strategy, its comparative benefits require validation in studies with matched risk populations and standardized protocols. Future research should prioritize risk-adapted treatment selection and toxicity mitigation strategies for high-risk cohorts.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251107275, Identifier CRD420251107275.